Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.virusres.2020.198141 http://scihub22266oqcxt.onion/10.1016/j.virusres.2020.198141 32846196!7443330!32846196     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32846196&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 219.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Virus+Res 2020 ; 288 (ä): 198141 Nephropedia Template TP {{tp|p=32846196|t=2020. Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development |pdf=|usr=}}{{32846196}} gab.com Text Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development JO: Virus Res http://www.kidney.de/pget.php?&tw=1&pmid=32846196 #FOAvip The recent outbreak of the betacoronavirus SARS-CoV-2 has become a significant concern to public health care worldwide. As of August 19, 2020, more than 22,140,472 people are infected, and over 781,135 people have died due to this deadly virus. In the USA alone, over 5,482,602 people are currently infected, and more than 171,823 people have died. SARS-CoV-2 has shown a higher infectivity rate and a more extended incubation period as compared to previous coronaviruses. SARS-CoV-2 binds much more strongly than SARS-CoV to the same host receptor, angiotensin-converting enzyme 2 (ACE2). Previously, several methods to develop a vaccine against SARS-CoV or MERS-CoV have been tried with limited success. Since SARS-CoV-2 uses the spike (S) protein for entry to the host cell, it is one of the most preferred targets for making vaccines or therapeutics against SARS-CoV-2. In this review, we have summarised the characteristics of the S protein, as well as the different approaches being used for the development of vaccines and/or therapeutics based on the S protein. Twit Text FOAVip Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development ????Virus Res http://www.kidney.de/pget.php?&tw=1&pmid=32846196 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32846196 #FOAvip English Wikipedia <ref>{{Cite pmid|32846196}}</ref> Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and therapeutic development #MMPMID32846196 Samrat SK; Tharappel AM; Li Z; Li H Virus Res 2020[Oct]; 288 (ä): 198141 PMID32846196show ga The recent outbreak of the betacoronavirus SARS-CoV-2 has become a significant concern to public health care worldwide. As of August 19, 2020, more than 22,140,472 people are infected, and over 781,135 people have died due to this deadly virus. In the USA alone, over 5,482,602 people are currently infected, and more than 171,823 people have died. SARS-CoV-2 has shown a higher infectivity rate and a more extended incubation period as compared to previous coronaviruses. SARS-CoV-2 binds much more strongly than SARS-CoV to the same host receptor, angiotensin-converting enzyme 2 (ACE2). Previously, several methods to develop a vaccine against SARS-CoV or MERS-CoV have been tried with limited success. Since SARS-CoV-2 uses the spike (S) protein for entry to the host cell, it is one of the most preferred targets for making vaccines or therapeutics against SARS-CoV-2. In this review, we have summarised the characteristics of the S protein, as well as the different approaches being used for the development of vaccines and/or therapeutics based on the S protein. |Angiotensin-Converting Enzyme 2[MESH] |Antibodies, Viral/*biosynthesis[MESH] |Antibody-Dependent Enhancement/drug effects[MESH] |Betacoronavirus/drug effects/*immunology/pathogenicity[MESH] |COVID-19[MESH] |COVID-19 Vaccines[MESH] |Clinical Trials as Topic[MESH] |Coronavirus Infections/epidemiology/immunology/*prevention & control/virology[MESH] |Genetic Vectors/chemistry/immunology[MESH] |Humans[MESH] |Immunogenicity, Vaccine[MESH] |Pandemics/*prevention & control[MESH] |Patient Safety[MESH] |Peptidyl-Dipeptidase A/genetics/immunology/metabolism[MESH] |Pneumonia, Viral/epidemiology/immunology/*prevention & control/virology[MESH] |Receptors, Virus/genetics/immunology/metabolism[MESH] |SARS-CoV-2[MESH] |Spike Glycoprotein, Coronavirus/genetics/*immunology/metabolism[MESH] |Vaccines, Attenuated[MESH] |Vaccines, DNA[MESH] |Vaccines, Subunit[MESH] |Vaccines, Virus-Like Particle/administration & dosage/biosynthesis/immunology[MESH]Prospect of SARS-CoV-2 spike protein: Potential role in vaccine and th(epmc).pdf DeepDyve Pubget Overpricing